By Billy Candra 
Deciding whether to start hormone therapy during the menopause transition, the life phase that’s the bookend to puberty and when a woman’s menstrual cycle stops, is a hotly debated topic. While hormone therapy (HT), or replacing the hormones that were previously produced by the body with synthetic medication, is widely recommended to manage bothersome symptoms like hot flashes and night sweats, a significant cloud of confusion has long lingered regarding its long-term effects, particularly on cardiovascular health. However, a new study led by Matthew Nudy, an assistant professor of medicine at the Penn State College of Medicine, is shedding crucial light on this complex issue, suggesting that long-term use of estrogen-based hormone therapies may, in fact, have beneficial effects on heart health.
A multi-institutional team, spearheaded by Nudy, meticulously analyzed data from hormone therapy clinical trials that were a foundational part of the Women’s Health Initiative (WHI)—a monumental, long-term national study focused on menopausal women. Their groundbreaking findings indicate that estrogen-based hormone therapy improved several biomarkers associated with cardiovascular health over an extended period. Most notably, the study provides compelling evidence that hormone therapy may significantly lower levels of lipoprotein(a), a largely genetic risk factor strongly linked to an elevated risk of heart attack and stroke. These pivotal findings, published recently in the journal Obstetrics & Gynecology, contribute substantially to the nuanced understanding of the intricate interplay between hormone therapy and cardiac well-being, offering invaluable additional guidance to both patients and their healthcare providers.
The Shifting Sands of Hormone Therapy Consensus
The medical community’s perspective on hormone therapy for menopausal women has undergone significant evolution over the past few decades. "The pendulum has been swinging back and forth as to whether hormone therapy is safe for menopausal women, especially from a cardiovascular disease perspective," Nudy stated, encapsulating the historical uncertainty. Initially, in the mid-20th century, HT was widely embraced as a panacea for aging, promising not just symptom relief but also protection against heart disease and osteoporosis. Prescriptions soared, and HT became a routine part of post-menopausal care.
However, this widespread enthusiasm was dramatically tempered in the early 2000s with the initial release of findings from the WHI. Launched in 1993, the WHI was an ambitious, multi-million dollar clinical trial designed to investigate major causes of death, disability, and poor quality of life in postmenopausal women. Its hormone therapy component was a randomized, placebo-controlled trial involving over 27,000 women. The initial reports from the WHI in 2002-2004 indicated an increased risk of breast cancer, stroke, heart attack, and blood clots in women taking combined estrogen and progestin therapy, particularly in older women or those more than 10 years past menopause onset. These findings led to a precipitous decline in HT prescriptions and a prevailing fear among both patients and physicians regarding its safety.
In the wake of these initial WHI reports, the medical community entered a period of reassessment. Subsequent re-analyses and a deeper dive into the WHI data, alongside other studies, began to reveal a more complex picture. It became clear that the age of initiation and the time since menopause onset were critical factors. "More recently, we’re recognizing that hormone therapy is safe in younger menopausal women within 10 years of menopause onset, who are generally healthy and who have no known cardiovascular disease," Nudy clarified, reflecting the current, more refined understanding. This recent study further strengthens this evolving perspective, providing specific mechanistic insights into potential cardiovascular benefits in appropriate populations.
Menopause and the Elevated Risk of Cardiovascular Disease
Beyond the commonly recognized symptoms like hot flashes and night sweats, the profound hormonal changes that accompany menopause usher in another major physiological shift: an increased risk of cardiovascular disease (CVD). Cardiovascular disease remains the leading cause of death for women globally, and this risk accelerates significantly after menopause. The decline in estrogen, a hormone known for its cardioprotective effects, can lead to a cascade of changes in a woman’s body. These include unfavorable shifts in cholesterol profiles, an increase in blood pressure, and an accelerated buildup of plaque in blood vessels, all of which substantially heighten the risk of heart attack and stroke. Prior to menopause, women typically have a lower risk of CVD compared to men of the same age, a protection largely attributed to estrogen. As estrogen levels plummet, this protective advantage diminishes, often aligning or even surpassing men’s risk later in life. Understanding these underlying physiological changes is crucial for appreciating the potential impact of hormone therapy on cardiovascular health.
Unpacking the Study’s Methodology and Key Findings
The research team behind this new study was particularly interested in understanding the long-term effect of hormone therapy on cardiovascular biomarkers, an area that had not been thoroughly evaluated over an extended period. Prior research in the field predominantly focused on short-term effects, often missing the enduring impact of hormonal interventions.
To address this gap, Nudy’s team conducted a meticulous re-analysis of biomarker data collected over a six-year period from a subset of women who had participated in an oral hormone therapy clinical trial, itself a component of the larger WHI. The participants, all post-menopausal and aged between 50 and 79 at the time of assignment, were randomly allocated to one of two groups: an estrogen-only group (for women who had undergone hysterectomy) and an estrogen plus progesterone group (for women with an intact uterus). These women provided blood samples at baseline and at subsequent intervals—one, three, and six years—allowing for a longitudinal assessment of cardiovascular health markers. In total, the team analyzed samples from 2,696 women, representing approximately 10% of the total participants in the original oral hormone therapy trial. This robust sample size and longitudinal design lend significant credibility to their findings.
The analysis revealed a generally beneficial effect of hormone therapy on most cardiovascular biomarkers in both the estrogen-only and the estrogen-plus-progesterone groups over time. Specifically:
- LDL cholesterol, often referred to as the "bad" cholesterol due to its role in arterial plaque buildup, was reduced by approximately 11%.
- Total cholesterol also saw a decrease in both groups.
- Insulin resistance, a precursor to type 2 diabetes and a significant risk factor for CVD, decreased.
- HDL cholesterol, the "good" cholesterol known for its protective role in transporting cholesterol away from arteries, increased by 13% in the estrogen-only group and 7% in the estrogen-and-progesterone groups.
However, the study also observed increases in triglycerides, a type of fat in the blood, and coagulation factors, proteins that play a role in blood clot formation. These increases align with some previously known effects of oral estrogen and are important considerations in patient assessment.
The Lipoprotein(a) Revelation: A Genetic Risk Factor Under Influence
Perhaps the most surprising and clinically significant finding for the research team was the substantial reduction in levels of lipoprotein(a) [Lp(a)], a unique type of cholesterol molecule. Lp(a) levels decreased by an impressive 15% in the estrogen-only group and 20% in the estrogen-plus-progesterone groups.
Lipoprotein(a) stands apart from other cholesterol types because its concentrations are primarily determined by genetics, making it largely resistant to lifestyle modifications like diet and exercise that can impact LDL or HDL levels. A high Lp(a) concentration is a strong, independent genetic risk factor associated with a significantly increased risk of heart attack and stroke, often at a younger age. It is also linked to an increased risk of aortic stenosis, a condition where calcium builds up on the heart valve, narrowing the opening and impeding blood flow. Globally, an estimated 1 in 5 people have elevated Lp(a), making it a widespread yet often undiagnosed risk factor.
"As a cardiologist, this finding is the most interesting aspect of this research," Nudy emphasized. "Currently, there are no medications approved by the Food and Drug Administration (FDA) to specifically lower lipoprotein(a). Here, we essentially found that oral hormone therapy significantly reduced lipoprotein(a) concentrations over the long-term." This discovery positions oral hormone therapy as a potential, albeit not FDA-approved for this indication, intervention for a challenging and prevalent cardiovascular risk factor that currently has limited therapeutic options. This finding opens new avenues for research and discussion regarding the comprehensive benefits of HT.
Disparities in Response: A Call for Further Research
Delving deeper into the data, the research team examined the findings by self-reported racial and ethnic group. They uncovered an intriguing and important observation: the decrease in lipoprotein(a) concentration was notably more pronounced among participants with American Indian or Alaska Native ancestry (a remarkable 41% reduction) and those with Asian or Pacific Islander ancestry (a 38% reduction).
The reasons behind these steeper reductions in specific racial and ethnic groups are not yet clear. Nudy acknowledged this ambiguity, stating that the team hopes to investigate this phenomenon further in future research studies. This finding underscores the critical importance of diverse representation in clinical trials and highlights the need for personalized medicine approaches that consider genetic and ethnic variations in treatment response. Understanding these disparities could lead to more targeted and effective therapeutic strategies for various populations.
Understanding Formulations and Metabolic Pathways
Nudy also provided crucial context regarding the specific type of estrogen therapy used in the clinical trial: conjugated equine estrogens (CEE), a commonly prescribed form of oral estrogen therapy. He explained that oral hormone therapy undergoes a process called "first pass metabolism" in the liver before being absorbed into the body. This hepatic processing can influence various metabolic pathways.
"That process could increase inflammatory markers, which may explain the rise in triglycerides and coagulation factors," Nudy elaborated. This insight is vital because it distinguishes oral formulations from other delivery methods. The increase in triglycerides and coagulation factors, while observed, might be attributable to this specific metabolic pathway unique to oral administration.
He further clarified this distinction by pointing out the availability of alternative formulations. "There are now other common formulations of estrogen hormone therapy like transdermal estrogen, which is administered through the skin," Nudy stated. "Newer studies have found that transdermal estrogen doesn’t increase triglycerides, coagulation factors or inflammatory markers." This highlights that not all hormone therapies are created equal, and the mode of delivery can significantly impact the metabolic profile and potential side effects. Transdermal patches, gels, or sprays bypass the liver’s first-pass metabolism, potentially offering a more favorable cardiovascular risk profile in certain individuals, a factor healthcare providers must weigh when counseling patients.
Evolving Clinical Guidance and Future Directions
The cumulative evidence, including this latest study, reinforces the evolving medical consensus regarding hormone therapy: it is not a one-size-fits-all solution, but rather a nuanced treatment option that requires careful, individualized consideration. The shift in understanding from a blanket warning to a more targeted approach emphasizes the importance of initiation timing, patient health status, and a thorough assessment of risks and benefits.
For those considering menopause hormone therapy, Nudy strongly recommended undergoing a comprehensive cardiovascular disease risk assessment. This recommendation stands even if the person has no prior history of heart attack or stroke, or has not been previously diagnosed with cardiovascular disease. Such an assessment provides healthcare providers with critical information, enabling them to make the most informed decision when considering the best option to treat menopause symptoms. This personalized approach aligns with modern medical practice, where shared decision-making between patient and provider is paramount.
It is important to reiterate that, despite these promising findings, "Currently, hormone therapy is not FDA-approved to reduce the risk of coronary artery disease or stroke," Nudy underscored. Its primary FDA-approved indications remain the management of moderate to severe menopausal symptoms and the prevention of osteoporosis. However, studies like this contribute significantly to the body of evidence that informs off-label discussions and future guideline developments.
The implications of this research are far-reaching. For millions of women entering or navigating menopause, it offers a more optimistic and scientifically grounded perspective on hormone therapy’s potential. It challenges previous oversimplified interpretations of the WHI data and encourages a return to thoughtful, individualized clinical judgment. This study not only illuminates potential benefits for heart health, particularly concerning lipoprotein(a), but also underscores the necessity of ongoing research into different HT formulations, optimal dosing, and the diverse responses across various populations. Future studies will need to explore the long-term impact of transdermal estrogen on lipoprotein(a) and other cardiovascular biomarkers, as well as delve deeper into the mechanisms behind the observed racial and ethnic differences in response. The ultimate goal is to empower women and their healthcare providers with the most accurate and comprehensive information to make informed decisions that enhance both quality of life and long-term health.
Other esteemed authors contributing to this significant paper include: Aaron Aragaki, Fred Hutchinson Cancer Center; Peter Schnatz and Xuezhi Jiang, Drexel University College of Medicine; JoAnn Manson, Brigham and Women’s Hospital, Harvard Medical School and Harvard T.H. Chan School of Public Health; Aladdin Shadyab, University of California San Diego; Su Yong Jung, University of California Los Angeles; Lisa Martin, The George Washington University; Robert Wild, University of Oklahoma Health Sciences Center; Catherine Womack, University of Tennessee Health Science Center; Charles Mouton, University of Texas Medical Branch; and Jacques Rossouw, formerly of the National Heart, Lung, and Blood Institute at the National Institutes of Health. Funding from the National Center for Advancing Translational Sciences provided essential support for this work.
